Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | NPC1 | O15118 | 7/20 | 0.36 |
| ▸ | RAB9A | P51151 | 7/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 3/20 | 0.35 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | RGS12 | O14924 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 4/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | HTR7 | P34969 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8328957 | 0.90 | ALDH1A1 (0.39) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL342420 | 0.83 | POLB (0.45) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL561821 | 0.82 | RAB9A (0.37) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL4445539 | 0.82 | NPC1 (0.36) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL1746858 | 0.81 | ALDH1A1 (0.35) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL7201002 | 0.79 | POLB (0.32) | ALDH1A1NPC1RAB9ASMN1; SMN2POLB | |
| SCHEMBL7112244 | 0.79 | EHMT2 (0.35) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL5133715 | 0.78 | LMNA (0.36) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL14157424 | 0.78 | POLB (0.41) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD | |
| SCHEMBL6052790 | 0.76 | SMN1; SMN2 (0.40) | ALDH1A1NPC1RAB9ASMN1; SMN2HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | AF CHEMICALS, LLC (US) | 2018-09-20 | — | — | US | claimed |
| WO-2006069366-A1 | METHODS OF PROTEIN PROFILING BY THIOLATION | INTEL CORPORATION (US) | 2006-06-29 | — | — | WO | claimed |
| US-20250241872-A1 | AFFINITY MEDICANT CONJUGATE | Illudent, Inc. (US) | 2025-07-31 | — | — | US | disclosed |
| US-12280021-B2 | Affinity medicant conjugate | AF CHEMICALS, LLC (US) | 2025-04-22 | — | — | US | disclosed |
| EP-4257186-B1 | AFFINITY MEDICANT CONJUGATES | AF CHEMICALS LLC (US) | 2024-12-04 | — | — | EP | disclosed |
| US-12116400-B2 | Albumin variants and conjugates | SARTORIUS ALBUMEDIX LIMITED (GB) | 2024-10-15 | — | — | US | disclosed |
| EP-4442251-A1 | FORMULATIONS AND USES THEREOF | Albumedix Ltd (GB) | 2024-10-09 | — | — | EP | disclosed |
| EP-3243835-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-04-10 | — | — | EP | disclosed |
| EP-3337816-B1 | ALBUMIN VARIANTS AND CONJUGATES | ALBUMEDIX LTD (GB) | 2024-02-14 | — | — | EP | disclosed |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | Califia Pharma Inc. (US) | 2023-11-23 | — | — | US | disclosed |
| EP-4257186-A2 | AFFINITY MEDICANT CONJUGATES | AF Chemicals LLC (US) | 2023-10-11 | — | — | EP | disclosed |
| EP-2650309-A1 | CONJUGATE OF FOLATE AND ANTIBODY, PREPARATION METHOD AND USE THEREOF | Wuhan Huayao Biopharmaceutical Co., Ltd (CN) | 2013-10-16 | — | — | EP | disclosed |
| US-20130259882-A1 | Conjugate of Folate and Antibody Preparation Method and Use Thereof | ZHEJIANG JIANFENG HANSHENG BIOSCIENCES CO., LTD. (CN) | 2013-10-03 | — | — | US | disclosed |
| EP-2604623-A2 | Transferrin variants and conjugates | Novozymes Biopharma DK A/S (DK) | 2013-06-19 | — | — | EP | disclosed |
| EP-2594583-A1 | Transferrin variants and conugates | Novozymes Biopharma DK A/S (DK) | 2013-05-22 | — | — | EP | disclosed |
| US-20110313133-A1 | Albumin variants and conjugates | NOVOZYMES A/S (DK) | 2011-12-22 | — | — | US | disclosed |
| US-20110124576-A1 | Transferrin Variants and Conjugates | NOVOZYMES A/S (DK) | 2011-05-26 | — | — | US | disclosed |
| WO-2007041502-A2 | METHODS FOR DETERMINING RESPONSIVENESS TO CANCER THERAPY | MONOGRAM BIOSCIENCES (US) | 2007-04-12 | — | — | WO | disclosed |
| EP-1583458-A2 | LIPOPHILIC ELECTROPHORETIC PROBES | Aclara BioSciences, Inc. (US) | 2005-10-12 | — | — | EP | disclosed |
| WO-2004010842-A2 | LIPOPHILIC ELECTROPHORETIC PROBES | ACLARA BIOSCIENCES, INC. (US) | 2004-02-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12280021-B2 | Affinity medicant conjugate | FCER2, HDGF, FCGR2A | ALDH1A1 3966/4885NPC1 1608/4885RAB9A 4490/4885 |
| US-20230372267-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ALDH1A1 3966/4885NPC1 1608/4885RAB9A 4490/4885 |
| US-20180263927-A1 | AFFINITY MEDICANT CONJUGATE | FCER2, HDGF, FCGR2A | ALDH1A1 3966/4885NPC1 1608/4885RAB9A 4490/4885 |
| US-20130259882-A1 | Conjugate of Folate and Antibody Preparation Method and Use Thereof | FOLR1, FOLR2, DHFR | ALDH1A1 2724/4885NPC1 4321/4885RAB9A 2517/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.